Taysha Gene Therapies Inc...
1.63
0.01 (0.62%)
At close: Jan 15, 2025, 3:59 PM
1.63
0.31%
After-hours Jan 15, 2025, 04:00 PM EST

Cashflow (Annual)

Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
Year FY23 FY22 FY21 FY20 FY19
Net Income -111.57M -166.01M -174.52M -60.01M -4.46M
Depreciation & Amortization 1.37M 1.17M 492.00K 9.00K n/a
Stock-Based Compensation 7.91M 18.04M 18.18M 3.35M n/a
Other Working Capital -15.72M 26.32M 14.17M -2.07M 540.00K
Other Non-Cash Items 47.28M 39.89M 10.14M 26.03M 3.92M
Deferred Income Tax n/a n/a n/a n/a n/a
Change in Working Capital -18.01M 18.52M 28.67M -111.00K 540.00K
Operating Cash Flow -73.02M -88.39M -117.04M -30.73M 135.00K
Capital Expenditures -7.37M -24.87M -21.55M -9.08M n/a
Acquisitions n/a n/a n/a n/a n/a
Purchase of Investments n/a n/a n/a n/a n/a
Sales Maturities Of Investments n/a n/a n/a n/a n/a
Other Investing Acitivies -3.48M -61.00K -6.25M -9.00M n/a
Investing Cash Flow -7.35M -24.93M -21.55M -9.08M n/a
Debt Repayment -3.45M n/a 39.96M n/a n/a
Common Stock Repurchased n/a n/a n/a n/a n/a
Dividend Paid n/a n/a n/a n/a n/a
Other Financial Acitivies -947.00K -1.15M -874.00K 125.21M n/a
Financial Cash Flow 136.39M 52.10M 39.08M 291.06M n/a
Net Cash Flow 56.02M -61.22M -99.51M 251.25M 135.00K
Free Cash Flow -80.39M -113.26M -138.60M -39.81M 135.00K